Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of Meloxicam Gel vs Tablet in Healthy Subjects
NCT02183077Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 1998
- Primary completion
- Nov 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Analysis of plasma concentration-time course after topical dose up to 264 hours and Ratio AUCss topical/AUC0-inf oral up to 96 hours. Started Sep 1998; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02183077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183077.